Diversifying Genomic Research & Clinical Trials
We believe diversifying genomic research and clinical trials to include more people of color increases knowledge about health issues and makes a difference in personalized healthcare for all.
WHAT WE DO
We provide biopharmaceutical companies, contract research organizations, and academic medical centers with a ready supply of willing & diverse participants for their genomic research & clinical trials.
We do this through e-DICT, which stands for Enhanced Diversity in Clinical Trials.
e-DICT is our HIPAA compliant platform utilizing artificial intelligence, machine learning, and predictive analytics to help automate the identification, education, engagement, and retention of willing & diverse genomic research and clinical trial participants. e-DICT works in conjunction with our "activation points" of trusted relationships with minority and underserved populations. We create value by decreasing the overall cost of drug development, increasing the speed of drug approval, integrating with virtual clinical trials, and aiding in the discovery of new drugs.
Opened in 2008, HudsonAlpha Institute for Biotechnology has become an international leader in genomics research and biotech education. HudsonAlpha leverages the synergy between discovery, education, medicine, and economic development in genomic sciences to improve the human condition around the globe. The state-of-the-art facilities bring together scientific researchers with entrepreneurs and educators. and fosters more than 40 diverse biotech companies on campus.
To learn more about HudsonAlpha, visit hudsonalpha.org
DELMONIZE SMITH, PHD
Co-Founder & Chief Executive Officer
Del has extensive management and leadership experience in healthcare, IT, education, and government. In addition to being a military veteran, Del's career includes work as an analyst at McKesson, Memorial Hermann Health Systems, and U.S. Oncology. He has successfully launched and sold two tech-related companies. Del earned a Bachelor of Business Administration from Faulkner University, a Master of Science in Management from Troy University, and a Ph.D. in Management from the University of Alabama.
Co-Founder & Chief Development Officer
Tiffany Jordan is an innovator and entrepreneur with 10 years of business management expertise.
She's experienced in all aspects of business formation, operation, strategic messaging, and marketing. In addition, she is a lifelong learner committed to staying on top of the best current and emerging business practices. She works hard to continue strengthening communities while fostering civic engagement through service and volunteering. At Acclinate Tiffany is able to utilize her relentless drive for diversity, equity, and inclusion to transform clinical research.
ACCLINATE WORKING TO ADDRESS HEALTHCARE DISPARITIES
Apr. 14, 2020
ACCLINATE GENETICS WINS LAUNCHPAD COMPETITION
Feb. 28, 2020
ACCLINATE SEEKS TO EDUCATE MINORITIES ON IMPORTANCE OF CLINICAL TRIALS
Sept. 5, 2019
ACCLINATE GENETICS WORKS TO FIGHT HEALTH DISPARITIES
Aug. 28, 2019
ACCLINATE WANTS MINORITIES REPRESENTED IN CLINICAL RESEARCH
Aug. 9, 2019
ACCLINATE PARTNERS WITH NATIONAL HBCU SPEECH & DEBATE
Mar. 22, 2020
ACCLINATE TEAMS WITH GOVERNOR'S OFFICE OF MINORITY AFFAIRS
Oct. 28, 2019
HUNTSVILLE COMPANY ON A MISSION TO TRANSFORM THE STATUS QUO OF CLINICAL RESEARCH
Aug. 12, 2019
ALABAMA-BASED GENETIC RESEARCH FIRM AT FOREFRONT TO DRIVE DIVERSE CLINICAL TRIAL PARTICIPATION
Aug. 10, 2019
MANAGEMENT SYSTEM AIMS TO ENHANCE DIVERSITY IN US CLINICAL TRIALS
Aug. 12, 2019